Estimating Long COVID-19 Prevalence Across Definitions and Forms of Sample Selection

Finasteride is effective for hair loss but can cause sexual dysfunction and mental health issues in some users, leading to a polarized debate on its risks. Some switch to alternatives like Dutasteride or topical treatments to avoid side effects.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Creatine does not cause or worsen hair loss, despite some anecdotal reports of hair thinning. The discussion emphasizes that these reports are not supported by scientific evidence.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

A 22-year-old stabilized hair loss with oral finasteride and minoxidil but sees minimal regrowth. They received conflicting transplant advice, with graft recommendations from 1,600 to 4,000, and concerns about diffuse thinning and donor area.